

### REMARKS

Claims 11-20, 23-30, 38-47, 50-51, 55, 57-58, 61-65, and 67-80 have been cancelled without prejudice. Claims 1, 21, 22, 31, 48, 49, 52, 56, and 59 have been amended. No new matter has been added. Entry of the present amendments is respectfully requested by Applicants.

Claims 1, 3-9, 21-22, 31, 33-37, 48-49, 52, 54, 56, 59, and 66 remain pending for examination.

#### Interview

Applicants herewith express their appreciation to the examiner for her telephonic interview with their undersigned representative on January 24, 2006. The interview is summarized in the Official Action mailed February 2, 2006. In the interview, the restriction requirement of January 9, 2006 was clarified to take into account the preliminary amendment filed September 1, 2005.

#### Restriction/election requirement

The examiner requires restriction under 35 USC §121 to one of the following groups of inventions. Claims 1, 3-9, 31, 33-37, 52, 54, and 59 are generic to Groups I-VII.

- |            |   |
|------------|---|
| Group I.   | Claims 11, 12, 38, 39, 61, and 72 drawn to haptens, immunogens, tracers, and antibodies derived from or based upon ritonavir  |
| Group II.  | Claims 11, 12, 38, 39, 61, and 72 drawn to haptens, immunogens, tracers, and antibodies derived from or based upon saquinavir |
| Group III. | Claims 11, 12, 38, 39, 61, and 72 drawn to haptens, immunogens, tracers, and antibodies derived from or based upon amprenavir |
| Group IV.  | Claims 11, 12, 38, 39, 61, and 72 drawn to haptens, immunogens, tracers, and antibodies derived from or based upon indinavir  |
| Group V.   | Claims 11, 12, 38, 39, 61, and 72 drawn to haptens, immunogens, tracers, and antibodies derived from or based upon nelfinavir |

Group VI. Claims 11, 12, 38, 39, 61, and 72 drawn to haptens, immunogens, tracers, and antibodies derived from or based upon lopinavir

Group VII. Claims 11, 12, 38, 39, 61, and 72 drawn to haptens, immunogens, tracers, and antibodies derived from or based upon atazanavir

Election


Applicants elect without traverse the invention of Group VI relating to lopinavir derivatives and antibodies produced therefrom.

\* \* \* \* \*

Applicants respectfully request the Examiner's entry of the present amendments and examination of claims 1, 3-9, 21-22, 31, 33-37, 48-49, 52, 54, 56, 59, and 66 as amended.

The Examiner is hereby authorized to charge any fees associated with this Amendment to Deposit Account No. 02-2958. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Marilyn L. Amick  
Reg. No. 30,444

Customer no. **23690**  
Phone: 317-521-7561